These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 26286301)

  • 1. Prophylactic implantable defibrillators for hypertrophic cardiomyopathy: disarray in the era of precision medicine.
    Grace A
    Circ Arrhythm Electrophysiol; 2015 Aug; 8(4):763-6. PubMed ID: 26286301
    [No Abstract]   [Full Text] [Related]  

  • 2. Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy.
    Vriesendorp PA; Schinkel AF; Liebregts M; Theuns DA; van Cleemput J; Ten Cate FJ; Willems R; Michels M
    Circ Arrhythm Electrophysiol; 2015 Aug; 8(4):829-35. PubMed ID: 25922410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A validation study of the European Society of Cardiology guidelines for risk stratification of sudden cardiac death in childhood hypertrophic cardiomyopathy.
    Norrish G; Ding T; Field E; McLeod K; Ilina M; Stuart G; Bhole V; Uzun O; Brown E; Daubeney PEF; Lota A; Linter K; Mathur S; Bharucha T; Kok KL; Adwani S; Jones CB; Reinhardt Z; Omar RZ; Kaski JP
    Europace; 2019 Oct; 21(10):1559-1565. PubMed ID: 31155643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of the 2014 European Society of Cardiology Sudden Cardiac Death Risk Prediction Model Among Various Phenotypes in Japanese Patients With Hypertrophic Cardiomyopathy.
    Nakagawa S; Okada A; Nishimura K; Hamatani Y; Amano M; Takahama H; Amaki M; Hasegawa T; Kanzaki H; Kusano K; Yasuda S; Izumi C
    Am J Cardiol; 2018 Dec; 122(11):1939-1946. PubMed ID: 30293654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM).
    O'Mahony C; Jichi F; Ommen SR; Christiaans I; Arbustini E; Garcia-Pavia P; Cecchi F; Olivotto I; Kitaoka H; Gotsman I; Carr-White G; Mogensen J; Antoniades L; Mohiddin SA; Maurer MS; Tang HC; Geske JB; Siontis KC; Mahmoud KD; Vermeer A; Wilde A; Favalli V; Guttmann OP; Gallego-Delgado M; Dominguez F; Tanini I; Kubo T; Keren A; Bueser T; Waters S; Issa IF; Malcolmson J; Burns T; Sekhri N; Hoeger CW; Omar RZ; Elliott PM
    Circulation; 2018 Mar; 137(10):1015-1023. PubMed ID: 29191938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of the 2014 European Society of Cardiology guideline on sudden cardiac death in hypertrophic cardiomyopathy: a systematic review and meta-analysis.
    O'Mahony C; Akhtar MM; Anastasiou Z; Guttmann OP; Vriesendorp PA; Michels M; Magrì D; Autore C; Fernández A; Ochoa JP; Leong KMW; Varnava AM; Monserrat L; Anastasakis A; Garcia-Pavia P; Rapezzi C; Biagini E; Gimeno JR; Limongelli G; Omar RZ; Elliott PM
    Heart; 2019 Apr; 105(8):623-631. PubMed ID: 30366935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy.
    Maron BJ; Shen WK; Link MS; Epstein AE; Almquist AK; Daubert JP; Bardy GH; Favale S; Rea RF; Boriani G; Estes NA; Spirito P
    N Engl J Med; 2000 Feb; 342(6):365-73. PubMed ID: 10666426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Independent Assessment of the European Society of Cardiology Sudden Death Risk Model for Hypertrophic Cardiomyopathy.
    Maron BJ; Casey SA; Chan RH; Garberich RF; Rowin EJ; Maron MS
    Am J Cardiol; 2015 Sep; 116(5):757-64. PubMed ID: 26183790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy.
    O'Mahony C; Tome-Esteban M; Lambiase PD; Pantazis A; Dickie S; McKenna WJ; Elliott PM
    Heart; 2013 Apr; 99(8):534-41. PubMed ID: 23339826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sudden death and hypertrophic cardiomyopathy: a review.
    Ly HQ; Greiss I; Talakic M; Guerra PG; Macle L; Thibault B; Dubuc M; Roy D
    Can J Cardiol; 2005 Apr; 21(5):441-8. PubMed ID: 15861263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy.
    Maron BJ; Estes NA; Maron MS; Almquist AK; Link MS; Udelson JE
    Circulation; 2003 Jun; 107(23):2872-5. PubMed ID: 12814983
    [No Abstract]   [Full Text] [Related]  

  • 12. [Risk stratification of sudden death in hypertrophic cardiomyopathy in 2016].
    Dubourg O; Charron P; Sirol M; Siam-Tsieu V; Mansencal N
    Presse Med; 2016 Oct; 45(10):903-910. PubMed ID: 27234906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
    Maron BJ; Spirito P; Shen WK; Haas TS; Formisano F; Link MS; Epstein AE; Almquist AK; Daubert JP; Lawrenz T; Boriani G; Estes NA; Favale S; Piccininno M; Winters SL; Santini M; Betocchi S; Arribas F; Sherrid MV; Buja G; Semsarian C; Bruzzi P
    JAMA; 2007 Jul; 298(4):405-12. PubMed ID: 17652294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noninvasive risk stratification prevents sudden death due to paroxysmal atrial fibrillation in hypertrophic cardiomyopathy.
    Limongelli G; Elliott PM; Pacileo G; Sarubbi B; Thaman R; Calabrò P; Vergara P; Iacomino M; Russo MG; Calabrò R
    J Cardiovasc Med (Hagerstown); 2006 Sep; 7(9):711-3. PubMed ID: 16932087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of sudden death in hypertrophic cardiomyopathy: bridging the gaps in knowledge.
    Weissler-Snir A; Adler A; Williams L; Gruner C; Rakowski H
    Eur Heart J; 2017 Jun; 38(22):1728-1737. PubMed ID: 27371714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypertrophic cardiomyopathy, sudden death, and implantable cardiac defibrillators: how low the bar?
    Nishimura RA; Ommen SR
    JAMA; 2007 Jul; 298(4):452-4. PubMed ID: 17652299
    [No Abstract]   [Full Text] [Related]  

  • 17. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy.
    Maron BJ; Spirito P; Ackerman MJ; Casey SA; Semsarian C; Estes NA; Shannon KM; Ashley EA; Day SM; Pacileo G; Formisano F; Devoto E; Anastasakis A; Bos JM; Woo A; Autore C; Pass RH; Boriani G; Garberich RF; Almquist AK; Russell MW; Boni L; Berger S; Maron MS; Link MS
    J Am Coll Cardiol; 2013 Apr; 61(14):1527-35. PubMed ID: 23500286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk assessment and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
    Slade AK; Camm AJ
    Arch Mal Coeur Vaiss; 1996 Feb; 89 Spec No 1():37-49. PubMed ID: 8734163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can sudden cardiac death be prevented?
    Maron BJ
    Cardiovasc Pathol; 2010; 19(6):329-35. PubMed ID: 20378375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk stratification in hypertrophic cardiomyopathy: fact or fiction?
    Hess OM
    J Am Coll Cardiol; 2003 Sep; 42(5):880-1. PubMed ID: 12957436
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.